Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
JEMPERLI▼ Mode of Action
JEMPERLI Mechanism of Action
How Can JEMPERLI Help Your Next Appropriate Patient?
JEMPERLI Is Indicated1
- JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
- JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
Reference
- Jemperli (dostarlimab) Summary of product characteristics January 2025 https://www.medicines.ie/ Last accessed April 2025.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 'or via online form'and include link to reporting form https://gsk.public.reportum.com/.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
PM-IE-DST-WCNT-240005 | March 2025
